(CercleFinance.com) – Novo Nordisk has reached an agreement to acquire Forma Therapeutics for $20 per share in cash, representing a total value of $1.1 billion.
Forma Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease and rare blood diseases.
The acquisition of Forma Therapeutics, including its lead development candidate, etavopivat, is part of Novo Nordisk’s strategy to complement and accelerate its scientific presence and product portfolio in hemoglobinopathies, a group diseases characterized by abnormal production or structure of the protein hemoglobin in red blood cells.
“By adding Forma’s differentiated approach to addressing unmet patient needs, we are taking a step forward in improving our sickle cell pipeline,” said Ludovic Helfgott, Executive Vice President and Head of Rare Diseases at Novo Nordisk.
‘We have the ambition to build a leading portfolio of stand-alone and combination treatments to address the complications and underlying causes of sickle cell disease.’
Copyright (c) 2022 CercleFinance.com. All rights reserved.